AtriCure (ATRC) Projected to Post Quarterly Earnings on Tuesday

AtriCure (NASDAQ:ATRC - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Tuesday, July 29th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $130.17 million for the quarter. AtriCure has set its FY 2025 guidance at -0.550--0.500 EPS.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. The firm had revenue of $123.62 million during the quarter, compared to analyst estimates of $122.92 million. AtriCure had a negative return on equity of 5.68% and a negative net margin of 7.95%. The business's revenue was up 13.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.28) EPS. On average, analysts expect AtriCure to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AtriCure Stock Down 1.8%

Shares of ATRC traded down $0.54 on Thursday, reaching $30.28. The stock had a trading volume of 188,496 shares, compared to its average volume of 563,929. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.88 and a current ratio of 4.11. AtriCure has a 12-month low of $20.20 and a 12-month high of $43.11. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -37.38 and a beta of 1.56. The company has a 50-day simple moving average of $32.34 and a 200-day simple moving average of $34.33.

Insiders Place Their Bets

In other AtriCure news, insider Vinayak Doraiswamy sold 2,500 shares of the stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $33.44, for a total transaction of $83,600.00. Following the sale, the insider directly owned 73,550 shares in the company, valued at approximately $2,459,512. This trade represents a 3.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AtriCure

Several institutional investors have recently modified their holdings of the business. Strs Ohio purchased a new position in AtriCure in the 1st quarter worth about $158,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of AtriCure by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company's stock worth $908,000 after acquiring an additional 1,230 shares during the period. AQR Capital Management LLC raised its holdings in shares of AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company's stock valued at $2,700,000 after purchasing an additional 837 shares during the last quarter. Jane Street Group LLC lifted its position in AtriCure by 658.3% during the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company's stock valued at $3,254,000 after purchasing an additional 87,553 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company's stock worth $27,830,000 after purchasing an additional 8,956 shares during the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. UBS Group dropped their target price on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. JMP Securities restated a "market outperform" rating and issued a $60.00 price objective on shares of AtriCure in a report on Wednesday, April 30th. Needham & Company LLC decreased their target price on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. BTIG Research reissued a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Finally, Canaccord Genuity Group cut their price target on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $50.67.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.